Incyte Corp. (0J9P)
LSE
Closed
Sep 24, 2026
Day's Range
122.5052 wk Range
81.50Overview - 0J9P - Incyte Corp.
Key Statistics
Valuation
Enterprise Value
20.56B
P/E (Trailing)
‪0.29‬
Price / Book
‪3.93‬
EV / EBITDA
‪10.58‬
Profitability
Profit Margin
‪27.70%‬
Operating Margin
‪41.89%‬
Return on Assets
‪16.83%‬
Return on Equity
‪30.66%‬
Ownership
Shares Outstanding
212.80M
Float
170.74M
Held by Insiders
‪1.84%‬
Held by Institutions
‪103.49%‬
Price stats
Beta
‪0.77‬
50-Day Avg
‪60.56‬
200-Day Avg
‪60.39‬
Market Cap - 0J9P - Incyte Corp.
Peers - 0J9P - Incyte Corp.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0J9PLSEIncyte Corp.26.41BMarket Cap+32.51%52-week change0.30P/E (Trailing)‪27.70%‬Profit Margin
- 0MGBLSEGenmab A/S198.39BMarket Cap+15.12%52-week change33.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock128.96BMarket Cap+20.00%52-week change0.53P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.95.05BMarket Cap+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.79.08BMarket Cap+20.99%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE49.68BMarket Cap+27.60%52-week change40.07P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA41.70BMarket Cap-23.88%52-week change120.47P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0J9P - Incyte Corp.
About
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
